This is a preview of subscription content, log in via an institution to check access.
Notes
2016 US dollars
Reference
Parikh ND, et al. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. Cancer : 29 Jun 2017. Available from: URL: http://doi.org/10.1002/cncr.30863
Rights and permissions
About this article
Cite this article
Regorafenib not cost effective as second-line agent for HCC. PharmacoEcon Outcomes News 782, 28 (2017). https://doi.org/10.1007/s40274-017-4159-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4159-5